Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.00
  • Today's Change-0.04 / -3.85%
  • Shares traded1.71m
  • 1 Year change-45.36%
  • Beta0.8464
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.

  • Revenue in HKD (TTM)11.10m
  • Net income in HKD-284.45m
  • Incorporated2014
  • Employees219.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tianda Pharmaceuticals Ltd384.68m-47.26m509.56m695.00--0.9358--1.32-0.022-0.0220.17890.25330.43412.974.46445,745.10-5.34---7.97--45.83---12.30--0.6748-9.510.1536--------------
3D Medicines Inc539.11m-495.99m557.73m198.00--0.5964--1.03-2.11-2.112.263.620.37464.945.792,722,764.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Lee's Pharmaceutical Holdings Ltd1.20bn63.06m694.83m1.06k11.020.40553.540.57950.10710.10712.042.910.44032.119.701,134,410.001.9813.332.5217.7651.4961.924.5036.200.74256.120.1323.59-14.61-1.53-67.44-47.49-12.19-31.34
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd925.32m189.30m733.93m678.003.880.41995.780.79320.33790.33791.653.120.35742.102.941,091,177.007.317.6710.2510.4875.4678.7920.4620.681.62--0.05027.22-0.00495.38-23.43-1.67-1.14--
Zhaoke Ophthalmology Ltd63.10m-250.42m748.21m297.00--0.3337--11.86-0.4597-0.45970.11584.110.02331.250.8868201,601.40-9.23---10.51--82.03---396.86--5.48-24.020.1114------5.47------
Fusen Pharmaceutical Co Ltd469.27m-98.90m749.96m1.14k--1.31--1.60-0.1326-0.13260.62990.76540.32121.683.35408,769.60-6.770.9678-13.961.7453.1851.95-21.082.590.526-2.270.403127.9515.024.13-4.83--0.2124--
Jbm (Healthcare) Ltd648.42m130.46m756.24m279.006.220.78794.121.170.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
Pak Fah Yeow International Ltd265.21m96.45m804.03m101.008.341.077.753.030.30940.30940.85072.410.28692.8423.532,600,118.0010.443.9911.324.1887.0580.7936.3721.274.225.260.0055100.6876.0612.94250.6623.0218.83-8.06
Zhongzhi Pharmaceutical Holdings Ltd2.25bn122.77m820.42m2.74k6.550.67223.900.3640.1450.1452.661.411.092.686.10852,889.205.997.699.1711.7557.5560.445.496.730.903343.870.151642.4612.2612.4153.0013.8617.653.22
Hbm Holdings Ltd562.82m166.02m952.48m158.005.500.95124.851.690.22570.22570.76341.300.32583.9616.673,179,801.009.59-54.6113.25-66.0495.5797.8129.42-400.283.448.140.3502--120.13127.06116.61---12.62--
Ascletis Pharma Inc11.13m-285.07m997.39m219.00--0.4212--89.63-0.2746-0.27460.01072.370.00411.343.5850,813.03-10.47-6.43-10.85-6.64-125.1735.67-2,561.69-243.3824.31-4.180.004--4.63-19.3954.04---20.44--
Jacobson Pharma Corporation Ltd1.47bn210.24m1.18bn1.72k5.390.49253.350.8040.10950.13910.76441.200.33112.476.37851,885.104.744.305.765.5742.2741.2514.3213.731.735.330.238240.6215.79-0.14011.31-3.0524.064.10
Essex Bio-Technology Ltd1.62bn262.89m1.28bn1.46k5.020.63644.040.79230.44990.44992.733.550.55872.622.731,093,064.009.0711.2012.1014.7389.7886.0116.2419.771.61--0.139716.1629.517.7222.113.567.297.39
SinoMab Bioscience Ltd2.23m-220.18m1.34bn215.00--4.40--600.98-0.2114-0.21140.00210.27980.0023----10,392.71-22.83-24.62-29.11-27.7226.80---9,853.75-4,451.74----0.6339------14.45--106.81--
VIVA Biotech Holdings2.20bn-350.72k1.36bn2.04k--0.32295.300.6184-0.0056-0.00561.071.950.26035.265.141,059,453.000.4017-1.390.5601-1.6833.6634.811.54-5.441.462.630.2884---9.4259.3178.03--31.98--
Data as of Sep 20 2024. Currency figures normalised to Ascletis Pharma Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

1.94%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 31 Dec 20237.89m0.78%
Dimensional Fund Advisors LPas of 31 May 20244.44m0.44%
JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 20232.75m0.27%
China Universal Asset Management Co., Ltd.as of 31 Dec 20231.82m0.18%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 20231.59m0.16%
China Southern Asset Management Co., Ltd.as of 31 Dec 2023500.00k0.05%
Dimensional Fund Advisors Ltd.as of 30 Jun 2024247.93k0.02%
SSgA Funds Management, Inc.as of 05 Sep 2024188.00k0.02%
American Century Investment Management, Inc.as of 05 Sep 2024186.00k0.02%
The Vanguard Group, Inc.as of 31 Jan 202327.98k0.00%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.